Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly...
Transcript of Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly...
![Page 1: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/1.jpg)
Nutraceutica e correzione del rischio cardiovascolare
Dott. ER CosentinoDipartimento Cardio-Toraco-Vascolare
Università degli Studi di Bologna
![Page 2: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/2.jpg)
![Page 3: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/3.jpg)
Perché fare prevenzione ?
![Page 4: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/4.jpg)
Entro il 2050 almeno 25 milioni di 80enni negli Stati Uniti
![Page 5: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/5.jpg)
Nel 2020 circa 600 milioni di persone saranno ad alto rischio per eventi cardiovascolari maggiori
![Page 6: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/6.jpg)
Deaths by cause in Europelatest available year
MEN WOMEN
European cardiovascular disease statistics 2008 http://www.ehnheart.org
![Page 7: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/7.jpg)
![Page 8: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/8.jpg)
![Page 9: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/9.jpg)
![Page 10: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/10.jpg)
![Page 11: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/11.jpg)
![Page 12: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/12.jpg)
![Page 13: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/13.jpg)
![Page 14: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/14.jpg)
![Page 15: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/15.jpg)
![Page 16: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/16.jpg)
![Page 17: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/17.jpg)
![Page 18: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/18.jpg)
![Page 19: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/19.jpg)
![Page 20: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/20.jpg)
![Page 21: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/21.jpg)
![Page 22: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/22.jpg)
![Page 23: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/23.jpg)
![Page 24: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/24.jpg)
![Page 25: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/25.jpg)
![Page 26: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/26.jpg)
![Page 27: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/27.jpg)
![Page 28: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/28.jpg)
PPrevenzionePrimaria
![Page 29: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/29.jpg)
PPrevenzionePrimaria
![Page 30: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/30.jpg)
PPrevenzionesecondaria
![Page 31: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/31.jpg)
PIntolleranti alle statine
![Page 32: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/32.jpg)
PIntollerantialle statine
![Page 33: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/33.jpg)
PIpercolesterolemiapoligenica primitiva
![Page 34: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/34.jpg)
![Page 35: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/35.jpg)
![Page 36: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/36.jpg)
![Page 37: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/37.jpg)
![Page 38: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/38.jpg)
Le antocianine in natura
![Page 39: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/39.jpg)
Il mais blu ricco di antocianine
![Page 40: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/40.jpg)
Il mais blu protegge dall’infarto?
![Page 41: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/41.jpg)
Le antocianine del mais riducono del 30% il danno da infarto del miocardio
![Page 42: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/42.jpg)
Il mais blu aumenta i livelli di Omega-3 marini nel sangue come una dieta ricca di pesce
![Page 43: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/43.jpg)
![Page 44: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/44.jpg)
Le antocianine negli alimenti
![Page 45: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/45.jpg)
Ried K et al. BMC Medicine 2010, 8:39
Cioccolato e pressione sistolica
![Page 46: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/46.jpg)
Cioccolato e pressione diastolica
Ried K et al. BMC Medicine 2010, 8:39
![Page 47: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/47.jpg)
The effect depends on age !
Cochrane Database of SystematicReviews 2012, Issue 8. Art. No.: CD008893.
![Page 48: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/48.jpg)
![Page 49: Nutraceutica e correzione del rischio cardiovascolare · eters differing from placebo significantly (P < 0.0001, P < 0.0001 , P < 0.0001, P = 0.001 , PC 0.0001, and P](https://reader030.fdocuments.net/reader030/viewer/2022040501/5e22e3affcf3cb7d0f42afcd/html5/thumbnails/49.jpg)